Advanced Cell Technology Scientist Dr. Robert Lanza Invited to Address The National Academy of Sciences at Stem Cell Policy Meeting.

Lanza to Discuss Company's Embryo-Preserving Technique to Derive New Stem Cell Lines

ALAMEDA, Calif. -- Advanced Cell Technology, Inc. (ACTC) (OTCBB:ACTC), applying proprietary human embryonic stem (ES) cell technology to the emerging field of regenerative medicine, announced today that Dr. Robert Lanza, Vice President of Research and Scientific Development of ACTC, will present before the National Academy of Sciences (NAS) at a special meeting to explore the latest developments in embryonic stem cell science and policy.

Dr. Lanza will make his presentation at the NAS's meeting of the Human Embryonic Stem Cell Research Advisory Committee, scheduled for November 7-8 in Washington, D.C. The meeting is dedicated to the furtherance of stem cell science and technology. His presentation will focus on ACTC's single-cell blastomere technique, which the company developed to derive new stem cell lines while preserving the embryo's potential for life and normal development.

The NAS, a prestigious society of distinguished scholars engaged in scientific research, has recruited Dr. Lanza to provide expert advice as they explore alternative ways to derive stem cells and make recommendations for the nation's public policy officials.

"We believe ACTC's technique for deriving stem cells without harming the embryo's potential for life can be an important consideration for the NAS as they form their recommendations to public officials," said William M. Caldwell IV, Chief Executive Officer of Advanced Cell Technology.

Advanced Cell Technology recently announced that company scientists demonstrated the ability to generate new human embryonic stem cell lines by adapting a proven technique already used at in vitro fertilization labs to determine genetic health. The ACTC approach maintains the embryo's potential for life, addressing one of the key debates in stem cell research.

ACTC's mission is to develop stem cell based treatments and therapies for a broad range of disease and injuries. Embryonic stem cells promise to provide a well-characterized and reproducible source of replacement tissue for human clinical studies. One of ACTC's lead development programs applies human embryonic stem cell (hESC)-derived retinal pigment epithelium (RPE) for the treatment of retinal degenerative diseases such as macular degeneration and retinitis pigmentosa. Another development program focuses on the use of hESC-derived hemangioblasts for vascular restoration of organs and limbs.

Since 1863, the nation's political leaders have often turned to the NAS for advice on the scientific and technological issues that frequently pervade policy decisions. Most of the NAS's science policy and technical work is conducted by its operating arm, the National Research Council, created expressly for this purpose. These non-profit organizations provide a public service by working outside the framework of government to ensure independent advice on matters of science, technology, and medicine.

Dr. Lanza will be speaking at 10:30 a.m. on Nov. 7. A live audio webcast of the event, along with Dr. Lanza's PowerPoint presentation, will be available at www.advancedcell.com.

About Advanced Cell Technology, Inc.

Advanced Cell Technology Inc. is a biotechnology company applying embryonic stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts. For more information, please visit: www.advancedcell.com.

For investor-specific information and resources, visit http://www.trilogy-capital.com/tcp/advanced_cell. To read or download Advanced Cell's Investor Fact Sheet, please visit http://www.trilogy-capital.com/tcp/advanced_cell/factsheet.html. To view recent stock quotes and news, visit http://www.trilogy-capital.com/tcp/advanced_cell/quote.html.

Forward-Looking Statements

Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended June 30, 2006.

Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.